SUPPLEMENTAL DIGITAL CONTENT 1

Table 1. Sensitivity analysis performed on the multivariate model for different types of adverse reactions, and limited to adverse reactions occurring at the second and third intakes. N= 515 women (1069 intakes overall, 554 second and third intakes)

	Vomiting (N=1069)		Fatigue (N=1069)		Dizziness (N=1069)		Serious AR (N=1069)		AR at second and third intakes (N=554)	
Covariate	OR [95% CI]	P	OR [95% CI]	P	OR [95% CI]	P	OR [95% CI]	P	OR [95% CI]	P
Timing of the MQ intake [*]:		<0.0001		<0.0001		<0.0001		<0.0001		___
first	1		1		1		1		___	
second or third	0.14 [0.09-0.21]		0.19 [0.12-0.29]		0.24 [0.17-0.34]		0.55 [0.40-0.77]		___	
HIV infection [†]:		0.023		0.046		0.002		0.001		0.154
Not infected	1		1		1		1		1	
Infected	0.18 [0.04-0.79]		0.30 [0.09-0.98]		0.16 [0.05-0.52]		0.08 [0.02-0.33]		0.35 [0.08-1.48]	
HIV viral load (copies/ml) [†]		0.146		0.587		0.044		0.013		0.061
<40 (undetectable)	1		1		1		1		1	
≥ (detectable)	2.57 [0.72-9.13]		0.70 [0.20-2.49]		2.87 [1.03-8.00]		5.58 [1.43-21.80]		2.87 [0.95-8.66]	
Scolarship [†]:		0.107		0.133		0.718		0.385		0.157
none or attended primary school	1		1		1		1		1	
attended secondary or superior	1.66 [0.95-2.91]		1.48 [0.89-2.47]		1.09 [0.69-1.71]		1.21 [0.79-1.84]		1.51 [0.85-2.65]	

school												
Age at enrolment (years) [†]:		0.794		0.033		<0.0001		0.722		0.016		
<25	1		1		1		1		1			
≥25	1.06 [0.67-1.70]		1.60 [1.04-2.47]		2.08 [1.40-3.08]		0.94 [0.66-1.33]		1.93 [1.13-3.29]			
HIV WHO clinical stage[†]:		0.090		0.131		0.817		0.118		0.363		
1-2	1		1		1		1		1			
3-4	0.23 [0.04-1.25]		0.17 [0.02-1.70]		1.15 [0.35-3.80]		2.53 [0.79-8.13]		0.52 [0.13-2.13]			
ARVs started concomittantly with a MQ intake [* ‡]:		0.60		0.422		0.112		0.002		UND		
no	1		1		1		1					
yes	1.64 [0.26-10.35]		2.23 [0.31-15.88]		3.53 [0.74-16.80]		9.52 [2.22-40.88]					

Covariates were tested simultaneously in a mixed effects logistic regression model, modelling random effects for the hospital (level 3) and the woman (level 2). For age, the cut-off is the median value. For analysis by type of adverse reaction, the whole sample was used. For analysis concerning adverse reactions after the second and third intakes, first intakes were excluded so the analysis was restricted to 554 observations. P values were obtained by use of Wald test. AR, adverse reaction; OR, odds ratio; CI, confidence interval; MQ, mefloquine; ARV, antiretroviral; UND, undetermined (only 2 observations were concerned so convergence was not reached, this covariate was removed from the model).

[*] covariates “at visit level”, i.e., level 1: with repeated measures, varying at each visit (inter and intra-women variance).

[†] Covariates “at woman level”, i. e., level 2: constant for each woman (inter-women variance only).

[‡] defined by less than one week interval between the MQ intake and the beginning of ARVs.